File S1 - TGF-β1/Smad Signaling Pathway Regulates Epithelial-to-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma: In Vitro and Clinical Analyses of Cell Lines and Nomadic Kazakh Patients from Northwest Xinjiang, China

Table S1, Dilution, pretreatment, immunostaining, positive controls, and source for the primary antibodies. Figure S1, ESCC cells treated with TGF-β1 (0, 1, 5, 10, 15 ng/mL) for 36 hrs. Quantitative analysis of MTT showed no significant differences among different doses. Figure S2, Western blot analysis of E-cadherin, N-cadherin, vimentin, P-Smad2 protein expression in ESCC cells treated with 5ng/ml TGF-β1 in the presence of 0, 1, 5, 10 µM SB431542. M. Effects of treatment of Eca109 cells with TGF-β1 (1, 5, or 10 ng/mL) on the expression of E-cadherin (molecular weight, 97 kDa), N-cadherin (molecular weight, 100 kDa), vimentin (molecular weight, 57 kDa), p-Smad2 (molecular weight, 52 kDa) and Smad7 (molecular weight, 51 kDa) by Western Blots. N. Quantitative analysis of treatment of Eca109 cells with TGF-β1 (1, 5, or 10 ng/mL), E-cadherin, N-cadherin, vimentin, P-Smad2 and Smad7 expression levels; Y axis: banding densities of test marker versus β-actin. Data are expressed as a significant change relative to the control. Each bar represents the mean±s.d. *, PP (DOC)